#USA #Boston #Tinostamustine #Knoa Pharma #sunobinop

Knoa Pharma's Pipeline Presentation at LSX Congress USA 2026

Knoa Pharma LLC, known for its dedication to enhancing public health, is making headlines by presenting its innovative pipeline assets at the upcoming LSX Congress USA 2026. Scheduled for September 23-24 in Boston, Massachusetts, the event will encompass a significant opportunity for the company to connect with potential partners interested in its groundbreaking therapeutics.

The spotlight will be on two of its most promising investigational drugs: tinostamustine and sunobinop. These assets aim to address critical health conditions ranging from cancer to substance use disorders and other serious ailments.

Tinostamustine: A Game-Changer in Oncology

Tinostamustine is a pioneering first-in-class drug that combines DNA alkylating activity with histone deacetylase (HDAC) inhibition, offering a two-fold therapeutic approach in a single agent. This drug is particularly noteworthy for its potential application in treating glioblastoma (GBM), an aggressive form of brain cancer, where treatment options have remained stagnant for over two decades. The first phase of clinical trials revealed encouraging results, indicating that tinostamustine, as an adjunct to standard chemotherapy, could significantly benefit newly diagnosed patients who are often challenging to treat.

The drug has gained orphan drug designation from the FDA, emphasizing its potential as a vital new treatment option in oncology. Presently, it is included in the GBM AGILE study, a pivotal phase 2/3 clinical trial that evaluates multiple therapies within a shared framework. This streamlined process not only accelerates drug development but also aims to set a new standard in GBM treatment protocols.

Sunobinop: Addressing Substance Use Disorders

Sunobinop, another first-in-class entity, acts as a nociceptin receptor agonist. This orally administered investigational drug is in the early phases of development for various indications, including alcohol use disorder (AUD), interstitial cystitis/bladder pain syndrome (IC/BPS), and overactive bladder (OAB). With its unique mechanism targeting the sensory pathways in the bladder and related areas, sunobinop is positioned to potentially transform treatment approaches for AUD, addressing cravings and consumption patterns that have long plagued this condition.

In the realm of bladder conditions, sunobinop's innovative approach aims to alleviate issues related to urination and pain. If successful, this could mark a significant advancement, offering a novel option to patients struggling with these debilitating symptoms.

Advancements and Partnerships

Knoa Pharma's commitment to scientific innovation is underscored by the words of David Saussy, the head of Licensing and Business Development at the company, who noted, "Our research and development are grounded in rigorous science. Sunobinop and tinostamustine are differentiated assets with encouraging clinical signals across multiple disease areas."

At the LSX Congress USA, Knoa Pharma aims to foster discussions with potential partners and stakeholders who share its vision of advancing public health through innovative solutions. Interested companies have the opportunity to learn more about Knoa Pharma's pipeline and possible collaboration during this significant industry event.

For further insights into the pipeline products or to explore partnership prospects, parties are encouraged to reach out via email directly at [email protected].

About Knoa Pharma

Founded with a mission to combat public health crises, Knoa Pharma focuses on developing therapies that target issues such as the opioid crisis and related disorders. With initiatives aimed at enhancing access to essential medications and driving research for unmet medical needs, the company remains dedicated to making meaningful impacts on patient care and public health. To learn more about their initiatives, visit www.knoapharma.com.